Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2591 - Head and neck cancer (HNC) and synchronic lung cancer: impact of the lung cancer on the management and prognosis of these patients. Data from the SYNCHRON GFPC 15-04 Study


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Head and Neck Cancers;  Thoracic Malignancies


Nicolas Paleiron


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


N. Paleiron1, L. SARAMON2, G. Robinet3, R. Gervais4, P. Fournel5, H. Le Caer6, H. Berard7, G. Valette2, R. Marianowski2, C. Chouaid8

Author affiliations

  • 1 Pneumology, HIA Brest, 29200 - Brest/FR
  • 2 Orl, CHU Brest Morvan, 29200 - Brest/FR
  • 3 Pneumologie, CHU Brest Morvan, 29200 - Brest/FR
  • 4 Oncologie, Centre Francois Baclesse, 14076 - Caen/FR
  • 5 Pneumologie, Institute de Cancerologie de la Loire, 42271 - St. Priest en Jarez/FR
  • 6 Pneumologie, Hôpital de St Brieuc, St brieuc/FR
  • 7 Pneumologie, Hôpital d'Instruction des Armées (HIA) Ste Anne, 83000 - Toulon/FR
  • 8 Pneumologie, CHI créteil, creteil/FR


Abstract 2591


Management of synchronous head and neck and lung cancer is almost difficult. The aim of this observational study was to describe the impact of the lung cancer on the management and prognosis of HNC.


Inclusion criteria were: consecutive patients diagnosed between January 2011 and December 2015 in 19 French centers with HNC and synchronous lung cancer (all stages). We describe: clinical characteristics, management and outcomes. Patient characteristics and treatment information was analyzed descriptively. Kaplan-Meier estimation was used to assess median overall survival.


The study included 132 patients: men: 83%; 63,7 years old, current smokers: 59,8%; performans status: 0 and 1 for 22% and 66% of the patients respectively; high rate of comorbidities: cardiovascular: 63%, COPD: 33%. Main histology for HNC was squamous: 98%, (in oral cavity: 24%, oropharyngeal: 26%, hypo-pharyngeal: 22% and laryngeal: 28%) T classification was T1, T2, T3 and T4 in 16%, 24%, 28% and 18% of cases respectively, and N classification was N0, N1, N2, N3, for 36%, 18%, 20% and 8% of cases respectively. The main treatment was surgery, 37,1%, and chemo-radiotherapy, 35,6%. The diagnosis of lung cancer impacts the HNC management in 38% of the cases. Median delay between HNC and first day treatment was 54 days. HNC progressive free survival rate was 68% at 2 years. Lung cancers were mostly localized (stages I: 46%, stages II: 10%), squamous: 39%, or adeno-carcinomas: 39%. Main treatments were surgery: 29%, mainly lobectomy, radiotherapy: 13%, radio-chemotherapy: 14% and chemotherapy alone: 35%. Seven patients didn’t receive active treatment. Median delay of treatment was 82,3 days. Lung cancer progressive free survival rate was 35% at 2 years. OS was 40% at 2 years, better for stage I - II lung cancers (55%).


Synchronous lung cancer at HNC diagnosis significantly impacts the management and outcomes of HNC. Specific recommendations and multidisciplinary approach should be elaborate to improve the management of these patients.

Clinical trial identification

Legal entity responsible for the study

Groupe Français de Pneumo-cancérologie


Boringer Pierre Fabre


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.